Ardent Health Partners Inc. has announced its financial results for the first quarter of 2025, reporting a total revenue of $1.50 billion, marking a 4.0% growth compared to the same period in the previous year. The company's net income attributable to Ardent Health reached $41 million, translating to $0.29 per diluted share, showing an increase from $27 million, or $0.21 per diluted share, in the first quarter of 2024. Adjusted EBITDA experienced a 2.5% increase year-over-year, reaching $98 million. In terms of admissions, Ardent Health reported a 7.6% growth year-over-year, totaling 41,389 admissions, while adjusted admissions rose by 2.7% to 84,536. However, outpatient surgeries saw a slight decline of 2.3%. The company has reaffirmed its full-year 2025 financial guidance, projecting total revenue between $6.2 billion and $6.45 billion and net income attributable to Ardent Health between $245 million and $285 million. Adjusted EBITDA is expected to be in the range of $575 million to $615 million. The company's guidance also anticipates adjusted admissions growth between 2.0% and 3.0%. Ardent Health continues to focus on operational excellence, achieving a reduction in supply costs and moderating the growth of professional fee expenses. The company is exploring inorganic growth opportunities, leveraging its strong balance sheet to pursue value-enhancing transactions and expressing interest in its joint venture model.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。